How We Treat ANCA-Associated Vasculitis: A Focus on the Maintenance Therapy.

IF 3 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Journal of Clinical Medicine Pub Date : 2025-01-02 DOI:10.3390/jcm14010208

Dario Roccatello, Roberta Fenoglio, Emanuele De Simone, Savino Sciascia

引用次数: 0

Abstract

Recent progress has notably improved outcomes for patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), namely granulomatosis with polyangiitis and microscopic polyangiitis. Since 2021, several international scientific societies have recommended rituximab (RTX) as the preferred primary treatment for maintaining remission in AAV patients. Decisions regarding retreatment with RTX are based on individual patient risk factors for disease flare-ups and the potential consequences of such flares. In reviewing available evidence and reporting our experiences at G. Bosco Hub Hospital in Turin, Italy, we explore various trials focusing on the maintenance therapy in AAV and discuss areas of unmet need.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

5.70

自引率

7.70%

发文量

6468

审稿时长

16.32 days

期刊介绍： Journal of Clinical Medicine (ISSN 2077-0383), is an international scientific open access journal, providing a platform for advances in health care/clinical practices, the study of direct observation of patients and general medical research. This multi-disciplinary journal is aimed at a wide audience of medical researchers and healthcare professionals. Unique features of this journal: manuscripts regarding original research and ideas will be particularly welcomed.JCM also accepts reviews, communications, and short notes. There is no limit to publication length: our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible.